Editorial
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 28, 2013; 19(40): 6703-6709
Published online Oct 28, 2013. doi: 10.3748/wjg.v19.i40.6703
Hepatitis C, stigma and cure
Rui Tato Marinho, David Pires Barreira
Rui Tato Marinho, David Pires Barreira, Department of Gastroenterology and Hepatology Hospital Santa Maria, Medical School of Lisbon, 1649-035 Lisboa, Portugal
Author contributions: Both of authors gave substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, and final approval of the version to be published.
Correspondence to: Rui Tato Marinho, MD, PhD, Department of Gastroenterology and Hepatology, Hospital Santa Maria, Medical School of Lisbon, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal. rui.marinho@mail.telepac.pt
Fax: +351-217-805678
Received: July 28, 2013
Revised: August 14, 2013
Accepted: August 17, 2013
Published online: October 28, 2013
Core Tip

Core tip: Around 3% of the world population, about 170-200 million people are infected with hepatitis C virus. The chronic consequences of the infection are liver cirrhosis and hepatocellular carcinoma, which appears in 20%-40% of the patients. Hepatitis C is not only a liver disease but also a mental, psychological, familiar, and social disease. The stigma that the infected person sometimes carries is tremendous. But, besides the “drama” of being infected, health professionals, family, society and infected patients, must be aware of the chance of real cure and definitive elimination of the virus. Step by step, the efficacy of the therapy for hepatitis C is rapidly increasing and with the new medications, the Direct Antiviral Agents-DAAs, is around 80%-90%.